ArticleVaccine2017
Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Coexistence with Staphylococcus aureus modulates the virulence and antibiotic resistance of Pseudomonas aeruginosa.Annals of clinical microbiology and antimicrobials · 2026Article
- Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.Infectious diseases and therapy · 2025Review
- An Immunoinformatics-Based Multi-Peptide Vaccine Provides Antibody-Mediated Protection AgainstVaccines · 2025Article
- Epidemiology ofFrontiers in public health · 2025Article
- Development and Evaluation of an Immunoinformatics-Based Multi-Peptide Vaccine againstVaccines · 2024Article
- Extensively and multidrug-resistant bacterial strains: case studies of antibiotics resistance.Frontiers in microbiology · 2024Review
- Putative novel outer membrane antigens multi-epitope DNA vaccine candidates identified by Immunoinformatic approaches to control Acinetobacter baumannii.BMC immunology · 2023Article
- The Prevalence of Multidrug-ResistantVaccines · 2023Review
- Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023Review
- A Short Peptide of Autotransporter Ata Is a Promising Protective Antigen for Vaccination AgainstFrontiers in immunology · 2022Article
- Insights intoFrontiers in immunology · 2022Review
- Mapping Global Prevalence ofVaccines · 2021Review
- Sequential Vaccination With HeterologousFrontiers in immunology · 2021Article
- Recent Advances in the Pursuit of an EffectivePathogens (Basel, Switzerland) · 2020Review
- Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.International journal of molecular sciences · 2020Review
- Antimicrobial Resistance in ESKAPE Pathogens.Clinical microbiology reviews · 2020Review
- The Mechanisms of Disease Caused byFrontiers in microbiology · 2019Review
- Thioredoxin Modulates Cell Surface Hydrophobicity inFrontiers in microbiology · 2019Article
- Thioredoxin-A is a virulence factor and mediator of the type IV pilus system in Acinetobacter baumannii.PloS one · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Multi-drug resistant Acinetobacter baumannii (MDR-Ab), an opportunistic pathogen associated with nosocomial and combat related infections, has a high mortality due to its virulence and limited treatment options. Deletion of the thioredoxin gene (TrxA) from a clinical isolate of MDR-Ab resulted in a 100-fold increase in 50% lethal dose (LD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.